Efficacy And Safety Of Rosuvastatin Combined With Ezetimibe On Familial Hypercholesterolemia

Background and purpose:Familial hypercholesterolemia(FH)is a common autosomal hereditary metabolic disease.It is characterized by a significant increase in serum low-density lipoprotein cholesterol(LDL-C),which is often associated with early-onset arteriosclerotic cardiovascular disease.The treatment of FH includes therapeutic lifestyle changes and drug treatment.Statins are the core drugs to reduce LDL-C,but it is often difficult to achieve LDL-C standard in FH patients with statins alone.Ezetimibe is currently the only cholesterol absorption inhibitor,which has been widely used in the treatment of dyslipidemia.At present,there are few studies on ezetimibe combined with statins in the real world of FH.We intend to study the efficacy and safety of ezetimibe combined with rosuvastatin in the treatment of familial hypercholesterolemia,so as to provide a new basis for the clinical treatment of familial hypercholesterolemia.method:48 FH patients who met the inclusion and exclusion criteria were randomly divided into observation group(n = 24)and control group(n= 24).The patients in the observation group were treated with rosuvastatin and ezetimibe(rosuvastatin 10 mg / D + ezetimibe 10 mg /D,oral before going to bed);The control group was treated with the same dose of rosuvastatin(rosuvastatin 10 mg / D,oral before going to bed)for 6 months.The levels of TC,LDL-C,TG and HDL-C were measured before treatment and 6 months after treatment.At the same time,the adverse reactions and alt,AST,CK,creatinine and other indexes were monitored during treatment.Result:There was no significant difference in the levels of TC,LDL-C and HDL-C between the observation group and the control group before treatment(P > 0.05).After 6 months of treatment,the levels of TC and LDL-C in the observation group were(5.32 ± 1.07)mmol / L and(3.55 ± 0.93)mmol / L respectively,and those in the control group were(5.78 ±1.44)mmol / L and(4.12 ± 0.86)mmol / L respectively.The levels of TC and LDL-C in the two groups were significantly higher than those in the same group before treatment(P < 0.05).After 6 months of treatment,there was significant difference in the levels of TC and LDL-C between the observation group and the control group(P <0.05).One case in the observation group stopped taking medicine after ALT increased more than 3 times.There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P > 0.05).Conclusion:Rosuvastatin combined with ezetimibe has better lipid-lowering effect than rosuvastatin alone in FH cases,and there is no significant difference in the safety of the two lipid-lowering strategies.